SECO 2023: Orasis Pharmaceuticals presents pipeline update at OIS
Paul Smith shares an update on Orasis Pharmaceutical's CSF-1 drug and what to expect this year.
SECO 2023: Keeping an eye on geographic atrophy
Mohammed Rafieetary, OD, shares key takeaways from his SECO 2023 presentation, "Advancing the understanding of geographic atrophy."
SECO 2023: Caring for myopic patients through lifestyle interventions
Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO, shares key takeaways from her SECO 2023 panel discussion, "Myopia management."
SECO 2023: Diabetes then and now
Paul Chous, MA, OD, FAAO, gives key takeaways from his 2023 SECO presentation on diabetes: then and now.
SECO 2023: Laser workshop for optometrists
Chris Wroten, OD, shares highlights from the hands-on laser workshop he co-led during SECO 2023.
This week in optometry: February 25-March 2
A look back on what's happened in optometry during the week of February 25-March 2.
SECO 2023: Drugs of the future
Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."
SECO 2023: Valuing your contact lens patients, while valuing yourself
Shalu Pal, BSc, OD, FAAO, shares key takeaways from the contact lens zpanel discussion she participated in.
SECO 2023: Contact lenses for presbyopic patients
Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key highlights from his portion of the "Presbyopia management panel," during SECO 2023 in Atlanta.
First patient enrolled in pivotal phase 3 clinical trial of BRM421 for dry eye disease
BRIM Biotechnology’s BRM421 is a first-in-class regenerative peptide and could relieve signs and symptoms of dry eye disease in as little as 2 weeks.
CooperVision’s MyDays Energys contact lenses hit US market
First 1-Day Lens that combines DigitalBoost and Aquaform technologies designed to deliver comfort for ‘always on’ digital lifestyles
Study: comparison of glisenings, PCO in hydrophobic acrylic IOLs
Investigators evaluated and compared the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed between 2 hydrophobic acrylic intraocular lenses (IOLs).
Controversies in Modern Eye Care meeting set for ophthalmologists, optometrists
One-day continuing education session offers latest insights and advancements.
Size plays role in injection of IOLs during cataract surgery
Smaller corneal incisions made during cataract surgery are linked with better visual outcomes and less frequent postoperative endophthalmitis.
Diversity, equity, inclusion, and belonging—in practice
As efforts continue across the globe, optometrists need to take action in clinics.
Poll results: How comfortable are you with including biosimilars in your treatment plans?
See the results from our recent poll!
Providing nutritional support for glaucoma management
Supplementing vision care with nutrition may protect ocular tissues.
This week in optometry: February 18-February 23
A look back on what's happened in optometry during the week of February 18-February 23.
Second FDA warning issued on bacterially contaminated eye care products
The FDA issued an update to the warning issued early in February and recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, and the firm agreed to initiate a recall.
Regeneron receives FDA acceptance, priority review of BLA for aflibercept 8 mg for wet AMD and DME
The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.
